Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/06/24
Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration StudyGlobeNewsWire • 07/25/24
Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ETGlobeNewsWire • 07/23/24
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial CapabilitiesGlobeNewsWire • 06/03/24
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences ConferenceGlobeNewsWire • 05/09/24
Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/07/24
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/07/24
Analysts Estimate Aquestive Therapeutics (AQST) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 04/30/24
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of NeurologyGlobeNewsWire • 04/12/24
Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024Seeking Alpha • 04/09/24
Aquestive Therapeutics (AQST) Ascends While Market Falls: Some Facts to NoteZacks Investment Research • 04/02/24
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common StockGlobeNewsWire • 03/25/24
Aquestive Therapeutics (AQST) Flat As Market Sinks: What You Should KnowZacks Investment Research • 03/22/24
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common StockGlobeNewsWire • 03/20/24
Strength Seen in Aquestive Therapeutics (AQST): Can Its 16.0% Jump Turn into More Strength?Zacks Investment Research • 03/18/24
Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA MeetingGlobeNewsWire • 03/14/24
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/06/24
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/05/24